Zhejiang Yatai Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jianwei Cen

Algemeen directeur

CN¥507.6k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2.6yrs
Gemiddelde ambtstermijn bestuur	2.6yrs

Recente managementupdates

Recent updates

Subdued Growth No Barrier To Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) With Shares Advancing 27%

Aug 27

CEO

Jianwei Cen (52 yo)

less than a year

Tenure

CN¥507,600

Compensatie

Mr. Jianwei Cen is General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd. from February 7, 2024. Mr. Cen was Deputy General Manager of Zhejiang Yatai Pharmaceutical Co. Ltd.from April 15, 2022 to Febru...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jianwei Cen	General Manager	less than a year	CN¥507.60k	geen gegevens
Jingyang Xu	Financial Director & Accounting Supervisor	2.6yrs	CN¥487.20k	geen gegevens
Wei Xu	Board Secretary	2.6yrs	CN¥487.40k	geen gegevens
Bao Kun Hu	Deputy General Manager	16.9yrs	CN¥404.00k	geen gegevens
Qin Shui Tan	Deputy General Manager	10.9yrs	CN¥453.60k	geen gegevens

2.6yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 002370 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.6 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Min Tu	Supervisor	2.7yrs	geen gegevens	geen gegevens
Xiaoming Huang	Director	2.6yrs	CN¥1.04m	geen gegevens
Cai Fu	Vice Chairman of the Board	2.6yrs	geen gegevens	geen gegevens
Lingbo Song	Non-Independent Director	2.6yrs	geen gegevens	geen gegevens
Wei Huang	Non-Independent Director	2.6yrs	CN¥359.60k	geen gegevens
Yajian Zhou	Non-Independent Director	2.6yrs	CN¥306.20k	geen gegevens
Haizhou Lu	Independent Director	2.6yrs	CN¥100.00k	geen gegevens
Yuehui Liu	Independent Director	2.6yrs	CN¥100.00k	geen gegevens
Lingjie Song	Chairman	2.6yrs	geen gegevens	geen gegevens
Min Cai	Independent Director	2.6yrs	CN¥100.00k	geen gegevens
Huaying Zhou	Supervisor	2.6yrs	geen gegevens	geen gegevens

2.6yrs

Gemiddelde duur

49yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 002370 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.6 jaar), wat duidt op een nieuw bestuur.

Zhejiang Yatai Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Recent updates

Third quarter 2024 earnings released: CN¥0.012 loss per share (vs CN¥0.028 loss in 3Q 2023)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

New major risk - Share price stability

Ningbo Heyi Culture Media Co., Ltd agreed to acquire Shanghai Xingaofeng Newsummit Biopharma Co., Ltd. from Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) for CNY 1.4 million.

Subdued Growth No Barrier To Zhejiang Yatai Pharmaceutical Co., Ltd. (SZSE:002370) With Shares Advancing 27%

Second quarter 2024 earnings released: EPS: CN¥0.018 (vs CN¥0.049 in 2Q 2023)

New minor risk - Share price stability

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 24, 2024

Full year 2023 earnings released: CN¥0.02 loss per share (vs CN¥0.25 loss in FY 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, Apr 19, 2024

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

New minor risk - Share price stability

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: CN¥0.028 loss per share (vs CN¥0.05 loss in 3Q 2022)

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Oct 28, 2023

Second quarter 2023 earnings released: EPS: CN¥0.049 (vs CN¥0.05 loss in 2Q 2022)

Full year 2022 earnings released: CN¥0.25 loss per share (vs CN¥0.43 loss in FY 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.10 loss in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 2Q 2021)

Zhejiang Yatai Pharmaceutical Co., Ltd., Annual General Meeting, May 20, 2022

First quarter 2022 earnings released: CN¥0.05 loss per share (vs CN¥0.04 loss in 1Q 2021)

High number of new and inexperienced directors

Zhejiang Yatai Pharmaceutical Co., Ltd. Announces Executive Appointments

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: CN¥0.10 loss per share (vs CN¥0.098 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 2Q 2020)

First quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.05 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.05 (vs CN¥3.86 loss in FY 2019)

Zhejiang Yatai Pharmaceutical Co., Ltd.(XSEC:002370) dropped from S&P Global BMI Index

New 90-day low: CN¥3.07

New 90-day low: CN¥3.62

New 90-day low: CN¥4.42

New 90-day low: CN¥4.77

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

Earnings released

New 90-day high - CN¥6.25

Zhejiang Yatai Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 27, 2020

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd